AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
Stock Information for Summit Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.